Guidance
Evidence-based recommendations on MRI-based technologies for assessing non-alcoholic fatty liver disease.
Guidance development process
How we develop NICE diagnostics guidance
This guidance replaces the NICE medtech innovation briefing on LiverMultiScan for liver disease (MIB181).